{"id":"W4417187153","doi":"10.1080/14796694.2025.2599082","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital","funders":"Seagen; Bristol-Myers Squibb","keywords":"Nivolumab; Brentuximab vedotin; Lymphoma; Ipilimumab; Chemoimmunotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001589285,0.0002846097,0.0007028301,0.0001746407,0.0001842716,0.00001744734,0.0001502119,0.0004681401,0.0001373713],"category_scores_gemma":[0.00006792293,0.0002316057,0.0002939237,0.0002006664,0.00006079077,0.00005150207,0.0000907816,0.0001306515,0.0001368743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001685316,"about_ca_system_score_gemma":0.001161902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004546941,"about_ca_topic_score_gemma":0.0001426641,"domain_scores_codex":[0.9983416,0.00007551908,0.0003736603,0.0005053054,0.0001567389,0.000547238],"domain_scores_gemma":[0.9987587,0.000308188,0.0001416526,0.0004919507,0.0001280921,0.0001714538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005410805,0.06318782,0.01234014,0.0006779583,0.000816645,0.0007568115,0.001052643,7.079321e-7,0.001136344,0.01579817,0.6813858,0.2174361],"study_design_scores_gemma":[0.1139133,0.001987825,0.01702215,0.00006702617,0.0004661617,0.00004819122,0.000406981,0.00008168562,0.001328058,0.0001374021,0.8643731,0.0001681151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8652391,0.01165859,0.0003792031,0.01922193,0.006562345,0.002637902,0.0002014165,0.0003203398,0.0937792],"genre_scores_gemma":[0.9732184,0.0006131826,0.001410885,0.005772902,0.001212119,0.000591188,0.0002931165,0.00004447296,0.01684368],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.217268,"threshold_uncertainty_score":0.9444605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009151288919165883,"score_gpt":0.2901132775739707,"score_spread":0.2809619886548048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}